Table 4.
Prevalence of interstitial lung disease in scleroderma patients classified by race and autoantibodies
| All | Caucasian American | African-American | Latin American | |
|---|---|---|---|---|
| N | 105a | 75 | 23 | 5 |
| Total | 44% (46/105) | 39%* (29/75) | 65%* (15/23) | 40% (2/5) |
| Topo I | 70%** (14/20) | 64% (7/11) | 75% (6/8) | 1/1 |
| RNAP III | 41% (7/17) | 43% (6/14) | 1/2 | NA |
| Centromere | 33%** (5/15) | 31% (4/13) | NA | 1/2 |
| U3RNP | 33% (3/9) | 0% (0/2) | 43% (3/7) | NA |
| Th | 25% (2/8) | 29% (2/7) | 1/1 | NA |
| U1RNP | 53% (10/19) | 40% (4/10) | 86% (6/7) | 0/2 |
| PM-Scl | 20% (1/5) | 20% (1/5) | NA | NA |
| None of the above | 50% (9/18) | 47% (7/15) | 2/2 | NA |
NA not applicable
*
p=0.06;
**
p=0.04
a
Includes one each of Asian and mixed patient